Իսրայել - եբրայերեն - Ministry of Health

dexcel ltd, israel - ranitidine as hydrochloride - טבליה - ranitidine as hydrochloride 150 mg - ranitidine - ranitidine - for the treatment of duodenal ulcer, benign gastric ulcer, oesophageal reflux disease and ulcers associated with the use of non-steroidal anti-inflammatory agents. for the prophylaxis of haemorrhage from stress ulceration.

Իսրայել - եբրայերեն - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Իսրայել - եբրայերեն - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Իսրայել - եբրայերեն - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Իսրայել - եբրայերեն - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Իսրայել - եբրայերեն - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Իսրայել - եբրայերեն - Ministry of Health

merck sharp & dohme israel ltd - fosaprepitant as fosaprepitant dimeglumine 150 mg - powder for solution for infusion - aprepitant - emend iv 150mg in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Իսրայել - եբրայերեն - Ministry of Health

bayer israel ltd - acarbose 50 mg - tablets - acarbose - treatment of niddm in patient's inadequatly controlled on diet alone or on diet and oral hypohlycaemia agents.

Իսրայել - եբրայերեն - Ministry of Health

bayer israel ltd - acarbose 100 mg - tablets - acarbose - treatment of niddm in patient's inadequatly controlled on diet alone or on diet and oral hypohlycaemia agents.

Իսրայել - եբրայերեն - Ministry of Health

rafa laboratories ltd - acarbose - טבליה - acarbose 50 mg - acarbose - acarbose - treatment of non-insulin dependent diabetes mellitus (niddm) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.